Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study
Authors' conclusion
AID appears superior to other insulin treatment modalities with CGM. Although bias may be present because of indications, AID should be considered the preferred choice for insulin pump therapy.
Study context
- Population
- Individuals with T1D using continuous glucose monitoring (CGM) at Steno Diabetes Center Copenhagen, Denmark; data September 2021 to August 2022, CGM used ≥20% of a 4-week periodof 6,314 attendees
- Participants
- 3,184 individuals
- Exposure
- Insulin treatment modalities with CGM: Multiple daily injection (MDI) vs SUP vs SAP vs automated insulin delivery (AID)
- MDIn = 1,622reference
- SUPn = 504
- SAPn = 354
- AIDn = 561
- Outcome
- Percentage of TIR (3.9-10.0 mmol/L) for each treatment group
Methodological detailsreal-world data, single-centre
- Real-world data
- Single-centre
Main finding
As reported in the abstract
TIR (3.9-10.0 mmol/L)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (95% CI) | |
|---|---|---|
| Achieving all recommended glycemic targets (TIR >70%, TAR <25%, TBR <4%)SAPvs MDI without alarm features | 2.4 (1.6–3.5) | |
| Achieving all recommended glycemic targets (TIR >70%, TAR <25%, TBR <4%)AIDvs MDI without alarm features | 9.4 (6.7–13.0) | |
| 0.050.21520Odds ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Glucose Monitoring Metrics in Individuals With Type 1 Diabetes Using Different Treatment Modalities: A Real-World Observational Study. Diabetes Care. Published 23 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →